(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally...
Stats | |
---|---|
今日成交量 | 1.21M |
平均成交量 | 339 509 |
市值 | 328.00M |
EPS | £0 ( 2024-04-29 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -2.01 |
ATR14 | £1.558 (0.48%) |
音量 相关性
Oxford BioMedica PLC 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Oxford BioMedica PLC 相关性 - 货币/商品
Oxford BioMedica PLC 财务报表
Annual | 2023 |
营收: | £89.54M |
毛利润: | £39.20M (43.78 %) |
EPS: | £-1.630 |
FY | 2023 |
营收: | £89.54M |
毛利润: | £39.20M (43.78 %) |
EPS: | £-1.630 |
FY | 2022 |
营收: | £139.99M |
毛利润: | £69.18M (49.42 %) |
EPS: | £-0.480 |
FY | 2021 |
营收: | £142.80M |
毛利润: | £82.64M (57.87 %) |
EPS: | £0.181 |
Financial Reports:
No articles found.
Oxford BioMedica PLC
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。